The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of Ephrin receptor kinase, especially EphB4, activity, especially for the curative and/or prophylactic treatment of proliferative diseases,...
At least 58 receptor tyrosine kinases (RTKs) and 32 non-receptor tyrosine kinases (NRTKs) have been found so far [2]. RTKs and NRTKs function by catalyzing the transfer of a phosphoryl group from a nucleoside triphosphate donor to the hydroxyl group of tyrosine residues on protein substrates...
Synthesis and biological evaluation of a series of novel salicylanilides as inhibitors of EGFR protein tyrosine kinases 合成和 EGFR 和 ErbB-2 酷氨酸 kinases 上的 salicylanilide 衍生物的二个系列的生物评估禁止的活动被进行.在 EGFR 酷氨酸 kinase 抑制上有一个另外的芳基组的那些在 ... N Ding,W Zh...
We discovered novel dual inhibitors of both receptor tyrosine kinases with interest for further studies to reduce inhibitor resistance developments in cancer treatment.doi:10.1080/14756366.2016.1247062Hempel, CorneliusTotzke, FrankSch?chtele, Christoph...
Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity Infection with human cytomegalovirus (HCMV) is a serious medical problem, particularly in immunocompromised individuals and neonates. The success of (val)g... C Hutterer,J Milbradt,...
Tyrosine kinase Inhibitors on signaling pathway are available at Adooq Bioscience. Check Tyrosine kinase pathway , inhibitors reviews and assay information.
tyrosine kinase and/or intracellular kinases that regulate cellular proliferation and tumor angiogenesis.2,6,7The selectivity of binding of various TKIs to their targets influences the potency, mechanism of action, selectivity, and safety profile of these agents.8Only select TKIs exhibit selectivity to...
Inhibitors of receptor tyrosine kinases (RTK) and 专利内容由知识产权出版社提供 专利名称:Inhibitors of receptor tyrosine kinases (RTK) and methods of use thereof 发明人:Bae, Jae Hyun,Lax, Irit,Schlessinger, Joseph 申请号:AU2011205297 申请日:20110113 公开号:AU2011205297A1 公开日:20120628 摘要:The ...
Also described herein are irreversible inhibitors of tyrosine kinases that have an accessible cysteine residue near an active site of the tyrosine kinase (referred herein as “Accessible Cysteine Kinases” or ACKs). Also described herein are irreversible inhibitors of any of the aforementioned tyrosine ...
The present invention relates to compounds that can inhibit the signal transduction of tyrosine kinases and non-receptor type and receptor type, to regulate and / or adjust. The compounds of the present invention has a core structure having a substituted pyrrole moiety. The present invention also ...